Medicamento aprovado pela União Europeia

O medicamento Vyndagel (tafamidis) é o primeiro remédio aprovado para uso para a Amiloidose Familiar (TTR-FAP).

Pfizer's Vyndaqel(R) (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)

Approval Represents a Major Advance, as Vyndaqel is the First and Only Medication Currently Approved to Delay Peripheral Neurologic Impairment in Stage 1 TTR-FAP Patients.